Literature DB >> 14642269

Caught in the act: alpha-synuclein is the culprit in Parkinson's disease.

Jason L Eriksen1, Ted M Dawson, Dennis W Dickson, Leonard Petrucelli.   

Abstract

Previous reports on Parkinson's disease indicate that genetic mutations in alpha-synuclein result in the aberrant accumulation of this protein, causing toxic gain of function leading to the development of Parkinson's. A recent report on the Iowan kindred, an extended pedigree with an autosomal dominant form of this disease, provides new mechanistic insight into Parkinson's disease by showing that an elevation in wild-type alpha-synuclein protein is sufficient to develop the early-onset form of the disorder. This review discusses how insights gained from these studies of alpha-synuclein may direct future research into Parkinson's disease.

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 14642269     DOI： 10.1016/s0896-6273(03)00684-6

Source DB:  PubMed          Journal:  Neuron        ISSN： 0896-6273            Impact factor:   17.173


  52 in total

1.  Biochemical and morphological consequences of human α-synuclein expression in a mouse α-synuclein null background.

Authors:  Kavita Prasad; Elizabeth Tarasewicz; Pamela A Ohman Strickland; Michael O'Neill; Stephen N Mitchell; Kalpana Merchant; Samnang Tep; Kathryn Hilton; Akash Datwani; Manuel Buttini; Sarah Mueller-Steiner; Eric K Richfield
Journal:  Eur J Neurosci       Date:  2011-01-28       Impact factor: 3.386

Review 2.  Metals, oxidative stress and neurodegenerative disorders.

Authors:  Klaudia Jomova; Dagmar Vondrakova; Michael Lawson; Marian Valko
Journal:  Mol Cell Biochem       Date:  2010-08-22       Impact factor: 3.396

3.  MicroRNA-7 facilitates the degradation of alpha-synuclein and its aggregates by promoting autophagy.

Authors:  Doo Chul Choi; Myungsik Yoo; Savan Kabaria; Eunsung Junn
Journal:  Neurosci Lett       Date:  2018-05-05       Impact factor: 3.046

Review 4.  Recognition of psychostimulants, antidepressants, and other inhibitors of synaptic neurotransmitter uptake by the plasma membrane monoamine transporters.

Authors:  Christopher K Surratt; Okechukwu T Ukairo; Suneetha Ramanujapuram
Journal:  AAPS J       Date:  2005-10-27       Impact factor: 4.009

5.  A neuroprotective role for angiogenin in models of Parkinson's disease.

Authors:  Trent U Steidinger; David G Standaert; Talene A Yacoubian
Journal:  J Neurochem       Date:  2010-12-22       Impact factor: 5.372

6.  Isolation of a human single chain antibody fragment against oligomeric alpha-synuclein that inhibits aggregation and prevents alpha-synuclein-induced toxicity.

Authors:  Sharareh Emadi; Hedieh Barkhordarian; Min S Wang; Philip Schulz; Michael R Sierks
Journal:  J Mol Biol       Date:  2007-03-07       Impact factor: 5.469

Review 7.  α-Synuclein nonhuman primate models of Parkinson's disease.

Authors:  David J Marmion; Jeffrey H Kordower
Journal:  J Neural Transm (Vienna)       Date:  2017-04-22       Impact factor: 3.575

8.  Dominant-positive HSF1 decreases alpha-synuclein level and alpha-synuclein-induced toxicity.

Authors:  Xu Liangliang; Hou Yonghui; E Shunmei; Gong Shoufang; Zhou Wei; Zou Jiangying
Journal:  Mol Biol Rep       Date:  2009-07-17       Impact factor: 2.316

9.  Ribosylation rapidly induces alpha-synuclein to form highly cytotoxic molten globules of advanced glycation end products.

Authors:  Lan Chen; Yan Wei; Xueqing Wang; Rongqiao He
Journal:  PLoS One       Date:  2010-02-04       Impact factor: 3.240

10.  Expression of human A53T alpha-synuclein in the rat substantia nigra using a novel AAV1/2 vector produces a rapidly evolving pathology with protein aggregation, dystrophic neurite architecture and nigrostriatal degeneration with potential to model the pathology of Parkinson's disease.

Authors:  James B Koprich; Tom H Johnston; M Gabriela Reyes; Xuan Sun; Jonathan M Brotchie
Journal:  Mol Neurodegener       Date:  2010-10-28       Impact factor: 14.195
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.